BerGenBio ASA (LTS:0RU5)

kr 9.9 0 (0%) Market Cap: 388.17 Mil Enterprise Value: 213.33 Mil PE Ratio: 0 PB Ratio: 2.62 GF Score: 54/100

Q3 2024 Bergenbio ASA Earnings Call Transcript
Nov 13, 2024

kr6.4 (-11.92%)

Earnings
Q2 2024 Bergenbio ASA Earnings Call Transcript
Aug 21, 2024

kr11.7

Earnings
Q1 2024 Bergenbio ASA Earnings Call Transcript
May 29, 2024

kr14.28 (-0.97%)

Earnings
Q3 2023 Bergenbio ASA Earnings Call Transcript
Nov 14, 2023

kr18.14 (-3.41%)

Earnings
Q2 2023 Bergenbio ASA Earnings Call Transcript
Aug 23, 2023

kr10.88 (+13.10%)

Earnings
Q4 2022 Bergenbio ASA Earnings Call Transcript
Feb 16, 2023

kr350.52

Earnings
Q3 2022 Bergenbio ASA Earnings Call Transcript
Nov 15, 2022

kr392.21 (-3.46%)

Earnings
Q2 2022 Bergenbio ASA Earnings Call Transcript
Aug 23, 2022

kr598.6 (-7.60%)

Earnings
Q1 2022 Bergenbio ASA Earnings Call Transcript
May 24, 2022

kr787.93 (-4.21%)

Earnings
Bergenbio ASA Strategy Update Transcript
May 04, 2022
Q4 2021 Bergenbio ASA Earnings Call Transcript
Feb 16, 2022

kr864.26 (-4.50%)

Earnings
Q3 2021 Bergenbio ASA Earnings Call Transcript
Nov 16, 2021

kr1040.23 (+3.16%)

Earnings
Q2 2021 Bergenbio ASA Earnings Call Transcript
Aug 17, 2021

kr1130.92 (-5.41%)

Earnings
Q1 2021 Bergenbio ASA Earnings Call Transcript
May 19, 2021

kr1172.1 (-9.39%)

Earnings
Bergenbio ASA to Discuss Top Line Data From Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients Call Transcript
May 18, 2021
Q4 2020 Bergenbio ASA Earnings Call Transcript
Feb 10, 2021

kr1680.9 (-4.09%)

Earnings
Q3 2020 Bergenbio ASA Earnings Call Transcript
Nov 17, 2020

kr1408.59 (-3.60%)

Earnings
Q2 2020 Bergenbio ASA Earnings Call Transcript
Aug 18, 2020

kr1817.9

Earnings
Q1 2020 Bergenbio ASA Earnings Call Transcript
May 19, 2020

kr1998.69 (-7.01%)

Earnings
Q4 2019 Bergenbio ASA Earnings Call Transcript
Feb 11, 2020

kr882.67

Earnings

Q3 2022 Bergenbio ASA Earnings Call Transcript

Nov 15, 2022 / 09:00AM GMT

Release Date Price: kr392.21 (-3.46%)

Transcript

Martin Olin

BerGenBio ASA - CEO

Good morning, and welcome to the third quarter 2022 update from BerGenBio. I'm Martin Olin, the CEO of the company. I just remind everyone about the formalities, forward-looking statements. BerGenBio, in summary, we are entirely focused on the development of selective AXL inhibitors for the treatment of aggressive diseases. Our lead compound, bemcentinib has already been studied in more than 600 patients as of today and is currently being advanced into significant opportunities.

First one, first-line non-small cell lung cancer in a particular subset of patients that carry a mutation in the STK11 gene. And we are moving forward with a Phase Ib/IIa study. I'll come back to that. We are also advancing bemcentinib in -- within hospitalized COVID-19 patients through a Phase IIb study.

We are laser focused to deliver clear value drivers in the next 12 to 18 months. This is the recent highlights. So we announced in the third quarter that we had dosed the first patient in the Phase IIb study under the EU-SolidAct platform enrolling up to 500 patients across

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.